Isochromanone-based urotensin-II receptor agonists

被引:29
作者
Lehmann, F
Currier, EA
Olsson, R
Hacksell, U
Luthman, K [1 ]
机构
[1] Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden
[2] ACADIA Pharmaceut Inc, San Diego, CA 92121 USA
[3] ACADIA Pharmaceut AS, DK-2600 Glostrup, Denmark
关键词
D O I
10.1016/j.bmc.2005.01.056
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of analogues of the selective non-peptide urotensin II (UII) receptor agonist 3-(4-chlorophenyl)-3-(2-dimethylaminoethyl)-isochroman- 1-one (AC-7954, 1) was synthesized and evaluated for UII agonist activity using a functional cell-based assay. The introduction of a methyl group in the 4-position resulted in a complete loss of activity, whereas substituents in the aromatic rings were beneficial. Sterically demanding amino groups were also detrimental to the activity. Several potent agonists were identified, six compounds being equally or more potent than 1. The most potent compound in the series was the 6,7-dimethyl analogue of 1 (16, pEC(50) 6.87). The racemate of 16 was resolved into the pure enantiomers using preparative straight phase HPLC. It was shown that the potency resides in the (+)-enantiomer (pEC(50) 7.11). The synthesized compounds seem to be selective for the UII receptor as no activities were observed at the closely related SSTR3 and 5 receptors. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3057 / 3068
页数:12
相关论文
共 37 条
[1]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[2]  
BAILEY DM, 1970, J ORG CHEM, V35, P4088, DOI 10.1021/jo00837a714
[3]   Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist [J].
Behm, DJ ;
Herold, CL ;
Ohlstein, EH ;
Knight, SD ;
Dhanak, D ;
Douglas, SA .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (04) :449-458
[4]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[5]   Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): High throughput assays in mammalian cells [J].
Bräuner-Osborne, H ;
Brann, MR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 295 (01) :93-102
[6]   Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins [J].
Burstein, ES ;
Spalding, TA ;
Brann, MR .
MOLECULAR PHARMACOLOGY, 1997, 51 (02) :312-319
[7]  
Burstein ES, 1997, J NEUROCHEM, V68, P525
[8]   A new ligand for the urotensin II receptor [J].
Camarda, V ;
Guerrini, R ;
Kostenis, E ;
Rizzi, A ;
Calò, G ;
Hattenberger, A ;
Zucchini, M ;
Salvadori, S ;
Regoli, D .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (03) :311-314
[9]   Somatostatin- and urotensin II-related peptides: Molecular diversity and evolutionary perspectives [J].
Conlon, JM ;
Tostivint, H ;
Vaudry, H .
REGULATORY PEPTIDES, 1997, 69 (02) :95-103
[10]   Structural requirements at the N-terminus of urotensin II octapeptides [J].
Coy, DH ;
Rossowski, WJ ;
Cheng, BL ;
Taylor, JE .
PEPTIDES, 2002, 23 (12) :2259-2264